Ribavirin Patent Expiration

Ribavirin is Used for treating infections and infestations by modulating cytokine responses in lymphocytes. It was first introduced by Bausch Health Us Llc in its drug Virazole on Dec 31, 1985. Other drugs containing Ribavirin are Copegus, Rebetol. 12 different companies have introduced drugs containing Ribavirin.


Ribavirin Patents

Given below is the list of patents protecting Ribavirin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Rebetol US6790837

(Pediatric)

Ribavirin syrup formulations Oct 05, 2023

(Expired)

Schering
Rebetol US6790837 Ribavirin syrup formulations Apr 05, 2023

(Expired)

Schering
Rebetol US6172046

(Pediatric)

Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection Mar 21, 2018

(Expired)

Merck Sharp Dohme
Rebetol US6172046

(Pediatric)

Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection Mar 21, 2018

(Expired)

Schering
Rebetol US6472373

(Pediatric)

Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection Mar 21, 2018

(Expired)

Merck Sharp Dohme
Rebetol US6472373

(Pediatric)

Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection Mar 21, 2018

(Expired)

Schering
Virazole US6150337 Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes Nov 21, 2017

(Expired)

Bausch
Rebetol US6172046 Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection Sep 21, 2017

(Expired)

Merck Sharp Dohme
Rebetol US6172046 Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection Sep 21, 2017

(Expired)

Schering
Rebetol US6472373 Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection Sep 21, 2017

(Expired)

Merck Sharp Dohme
Rebetol US6472373 Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection Sep 21, 2017

(Expired)

Schering
Rebetol US6177074

(Pediatric)

Polyethylene glycol modified interferon therapy May 01, 2017

(Expired)

Merck Sharp Dohme
Rebetol US6177074

(Pediatric)

Polyethylene glycol modified interferon therapy May 01, 2017

(Expired)

Schering
Rebetol US6461605

(Pediatric)

Continuous low-dose cytokine infusion therapy May 01, 2017

(Expired)

Merck Sharp Dohme
Rebetol US6461605

(Pediatric)

Continuous low-dose cytokine infusion therapy May 01, 2017

(Expired)

Schering
Rebetol US6524570

(Pediatric)

Polyethylene glycol modified interferon therapy May 01, 2017

(Expired)

Merck Sharp Dohme
Rebetol US6524570

(Pediatric)

Polyethylene glycol modified interferon therapy May 01, 2017

(Expired)

Schering
Rebetol US6177074 Polyethylene glycol modified interferon therapy Nov 01, 2016

(Expired)

Merck Sharp Dohme
Rebetol US6177074 Polyethylene glycol modified interferon therapy Nov 01, 2016

(Expired)

Schering
Rebetol US6461605 Continuous low-dose cytokine infusion therapy Nov 01, 2016

(Expired)

Merck Sharp Dohme
Rebetol US6461605 Continuous low-dose cytokine infusion therapy Nov 01, 2016

(Expired)

Schering
Rebetol US6524570 Polyethylene glycol modified interferon therapy Nov 01, 2016

(Expired)

Merck Sharp Dohme
Rebetol US6524570 Polyethylene glycol modified interferon therapy Nov 01, 2016

(Expired)

Schering



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ribavirin's patents.

Given below is the list recent legal activities going on the following patents of Ribavirin.

Activity Date Patent Number
Patent litigations
Correspondence Address Change 26 Aug, 2011 US6790837
Post Issue Communication - Certificate of Correction 05 Mar, 2007 US6790837
Post Issue Communication - Certificate of Correction 26 Oct, 2005 US6461605
Recordation of Patent Grant Mailed 14 Sep, 2004 US6790837
Patent Issue Date Used in PTA Calculation 14 Sep, 2004 US6790837
Issue Notification Mailed 26 Aug, 2004 US6790837
Receipt into Pubs 20 Aug, 2004 US6790837
Dispatch to FDC 19 Aug, 2004 US6790837
Application Is Considered Ready for Issue 19 Aug, 2004 US6790837
Receipt into Pubs 18 Aug, 2004 US6790837


Ribavirin's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Ribavirin Generic API Manufacturers

Several generic applications have been filed for Ribavirin. The first generic version for Ribavirin was by Chartwell Rx Sciences Llc and was approved on Apr 6, 2004. And the latest generic version is by Navinta Llc and was approved on Oct 6, 2016.

Given below is the list of companies who have filed for Ribavirin generic, along with the locations of their manufacturing plants worldwide.